75%Confidence
0Views
FDASource
2026-04-07Date
Summary
Amerisource Health Services faces a Class II recall for Meclizine tablets due to failed specifications, indicating potential distribution of substandard product. This could strain relationships with healthcare providers and prompt tighter inventory controls across their network.
Actionable: Review Amerisource's quality assurance protocols for distributed pharmaceuticals to prevent future incidents.
AI Confidence: 75%
Data Points
firmAmerisource Health Services LLC
classificationClass II
statusOngoing
distributionU.S. Nationwide
productMeclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mg Individual Dose ( NDC 60687-775-11), Rx Only, Dis
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now